Episodic Pivot News Headlines
Headlines
AHM | Catalyst: Analyst Upgrade | Float: 49M | EPS Rtg: | RS:
Shares of American Home Mortgage Investment Corp. spiked Friday after an RBC Capital Markets analyst issued a report saying the stock has fallen much too steeply.
HIFN | Catalyst: Earnings Acceleration | Float: 12M | EPS Rtg: 64 | RS: 80
Hifn Swings to Fiscal 3Q Profit
Hifn reported earnings for the quarter ending June 30 of $284,000, or 2 cents per share, compared with losses of $2.2 million, or 16 cents per share, during the same quarter a year ago.
Revenue fell 4.7 percent to $11.7 million from $12.3 million in the year-ago quarter.
Hifn's fiscal third quarter operating costs declined 22 percent to $11.7 million, compared with $14.9 million during the same quarter a year ago.
ISRG | Catalyst: Earnings Acceleration | Float: 37M | EPS Rtg: 98 | RS: 96
Intuitive Surgical stock jumps 32% on strong earnings
company posted an 84 percent increase in second quarter net income.
The company, which makes the da Vinci robotic device that enables surgeons to operate more precisely, has seen its stock more than double over the past year.
On Thursday, Intuitive reported profit of $30.7 million or 79 cents a share, up from $16.7 million or 44 cents a year ago.
Revenue grew 61 percent to $140.2 million. The company said its device -- which is controlled by a doctor who watches a three-dimensional, high-definition monitor -- is now used by more than 500 hospitals for procedures that include repairing heart valves and removing cancerous tissue.
KCI | Catalyst: Earnings Acceleration | Float: 59M | EPS Rtg: 93 | RS: 91
Kinetic Concepts posts 25% rise in earnings, lifts guidance
NCST | Catalyst: Biotech/Drug Approval | Float: | EPS Rtg: 37 | RS: 82
Nucryst shares soar on FDA clearance for topical cream
OAKF | Catalyst: Takeover, merger etc | Float: 4M | EPS Rtg: 30 | RS: 82
WesBanco to pay $38-share for Oak Hill Financial
OMCL | Catalyst: Earnings Acceleration | Float: 28m | EPS Rtg: 94 | RS: 80
Omnicell 2Q Profit Surges
net income of $18.1 million, or 55 cents per share, compared with $2.1 million, or 7 cents per share, last year. The recent period's results included a $12.8 million, or 39 cents per share, income tax benefit from the partial reversal of a valuation allowance on some deferred tax assets.
Excluding share-based compensation and other one-time items, Omnicell reported a profit of $7.8 million, or 24 cents per share.
Revenue rose to $51.8 million from $36.3 million a year ago with product sales surging to $42.7 million from $28.5 million.
Analysts polled by Thomson Financial expected a profit of 23 cents per share on sales of $48.7 million.
PGNX | Catalyst: Biotech/Drug Approval | Float: 25m | EPS Rtg: 15 | RS: 28
Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
TPX | Catalyst: Earnings Acceleration | Float: 81M | EPS Rtg: 93 | RS: 94
Tempur-Pedic's profit rises; shares up second-quarter net earnings of $32.9 million, or 39 cents a share, up 26% from $26.1 million, or 30 cents a share, in the year-ago quarter. Revenue rose 18% to $257.6 million from $219 million last year. Analysts polled by Thomson Financial were expecting, on average, a per-share profit of 35 cents on revenue of $245 million. The company also raised its 2007 outlook and now expects earnings of $1.63 to $1.66 a share on revenue of $1.07 billion to $1.09 billion. Tempur-Pedic also said it has approved a new stock buyback plan of up to $200 million.
WSM | Catalyst: Analyst Upgrade | Float: 91M | EPS Rtg: 52 | RS: 51
Williams-Sonoma Climbs As Cowen Analyst Says Turnaround Progressing Well
No headlines
DUA
GMO
NWRE
PUK
PVG
REFR
SIG
TFSL
Bearish Episodic Pivots
Headlines
ACTS | Catalyst: Poor Earnings -> lower-than-expected income of $9.8 million, or 11 cents per American depositary share, in the second quarter -- nearly half of last year's EPS.
ANET | Catalyst: Poor Earnings -> slid 11.9% after posting non-GAAP second-quarter earnings of 7 cents a share, which falls 4 cents short of Thomson Financial's estimates. The firm also predicted that third-quarter per-share income will be half of what Wall Street is expecting.
BKI | Catalyst: Analyst Downgrade -> Buckeye Tech downgraded by UBS
BVF | Catalyst: Biotech/Drug Setback -> Biovail sent reeling as FDA rejects application
CYBS | Catalyst: Analyst Downgrade -> CyberSource downgraded by JMP Securities and Needham & Co
GPCB | Catalyst: Biotech/Drug Setback -> GPC Biotech Shares Plunge on FDA Concern
JADE | Catalyst: Other -> Notified of possible delisting from The Nasdaq Global Market
PLL | Catalyst: Tax Inquiry -> Pall shares sink as company probes potential tax issues
PSSI | Catalyst: Earnings Guidance Lowered -> PSS World Medical Expects Lower Profit
SON | Catalyst: Poor Earnings -> Sonoco misses expectations, shares tumble
SPPI | Catalyst: Biotech/Drug Setback -> Biotech Stocks: Drug stocks mixed; Biovail tumbles on FDA rejection
WHR | Catalyst: Poor sales
X | Catalyst: Analyst Downgrade
No headlines
BIDU
GS
MLM
AHM | Catalyst: Analyst Upgrade | Float: 49M | EPS Rtg: | RS:
Shares of American Home Mortgage Investment Corp. spiked Friday after an RBC Capital Markets analyst issued a report saying the stock has fallen much too steeply.
HIFN | Catalyst: Earnings Acceleration | Float: 12M | EPS Rtg: 64 | RS: 80
Hifn Swings to Fiscal 3Q Profit
Hifn reported earnings for the quarter ending June 30 of $284,000, or 2 cents per share, compared with losses of $2.2 million, or 16 cents per share, during the same quarter a year ago.
Revenue fell 4.7 percent to $11.7 million from $12.3 million in the year-ago quarter.
Hifn's fiscal third quarter operating costs declined 22 percent to $11.7 million, compared with $14.9 million during the same quarter a year ago.
ISRG | Catalyst: Earnings Acceleration | Float: 37M | EPS Rtg: 98 | RS: 96
Intuitive Surgical stock jumps 32% on strong earnings
company posted an 84 percent increase in second quarter net income.
The company, which makes the da Vinci robotic device that enables surgeons to operate more precisely, has seen its stock more than double over the past year.
On Thursday, Intuitive reported profit of $30.7 million or 79 cents a share, up from $16.7 million or 44 cents a year ago.
Revenue grew 61 percent to $140.2 million. The company said its device -- which is controlled by a doctor who watches a three-dimensional, high-definition monitor -- is now used by more than 500 hospitals for procedures that include repairing heart valves and removing cancerous tissue.
KCI | Catalyst: Earnings Acceleration | Float: 59M | EPS Rtg: 93 | RS: 91
Kinetic Concepts posts 25% rise in earnings, lifts guidance
NCST | Catalyst: Biotech/Drug Approval | Float: | EPS Rtg: 37 | RS: 82
Nucryst shares soar on FDA clearance for topical cream
OAKF | Catalyst: Takeover, merger etc | Float: 4M | EPS Rtg: 30 | RS: 82
WesBanco to pay $38-share for Oak Hill Financial
OMCL | Catalyst: Earnings Acceleration | Float: 28m | EPS Rtg: 94 | RS: 80
Omnicell 2Q Profit Surges
net income of $18.1 million, or 55 cents per share, compared with $2.1 million, or 7 cents per share, last year. The recent period's results included a $12.8 million, or 39 cents per share, income tax benefit from the partial reversal of a valuation allowance on some deferred tax assets.
Excluding share-based compensation and other one-time items, Omnicell reported a profit of $7.8 million, or 24 cents per share.
Revenue rose to $51.8 million from $36.3 million a year ago with product sales surging to $42.7 million from $28.5 million.
Analysts polled by Thomson Financial expected a profit of 23 cents per share on sales of $48.7 million.
PGNX | Catalyst: Biotech/Drug Approval | Float: 25m | EPS Rtg: 15 | RS: 28
Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
TPX | Catalyst: Earnings Acceleration | Float: 81M | EPS Rtg: 93 | RS: 94
Tempur-Pedic's profit rises; shares up second-quarter net earnings of $32.9 million, or 39 cents a share, up 26% from $26.1 million, or 30 cents a share, in the year-ago quarter. Revenue rose 18% to $257.6 million from $219 million last year. Analysts polled by Thomson Financial were expecting, on average, a per-share profit of 35 cents on revenue of $245 million. The company also raised its 2007 outlook and now expects earnings of $1.63 to $1.66 a share on revenue of $1.07 billion to $1.09 billion. Tempur-Pedic also said it has approved a new stock buyback plan of up to $200 million.
WSM | Catalyst: Analyst Upgrade | Float: 91M | EPS Rtg: 52 | RS: 51
Williams-Sonoma Climbs As Cowen Analyst Says Turnaround Progressing Well
No headlines
DUA
GMO
NWRE
PUK
PVG
REFR
SIG
TFSL
Bearish Episodic Pivots
Headlines
ACTS | Catalyst: Poor Earnings -> lower-than-expected income of $9.8 million, or 11 cents per American depositary share, in the second quarter -- nearly half of last year's EPS.
ANET | Catalyst: Poor Earnings -> slid 11.9% after posting non-GAAP second-quarter earnings of 7 cents a share, which falls 4 cents short of Thomson Financial's estimates. The firm also predicted that third-quarter per-share income will be half of what Wall Street is expecting.
BKI | Catalyst: Analyst Downgrade -> Buckeye Tech downgraded by UBS
BVF | Catalyst: Biotech/Drug Setback -> Biovail sent reeling as FDA rejects application
CYBS | Catalyst: Analyst Downgrade -> CyberSource downgraded by JMP Securities and Needham & Co
GPCB | Catalyst: Biotech/Drug Setback -> GPC Biotech Shares Plunge on FDA Concern
JADE | Catalyst: Other -> Notified of possible delisting from The Nasdaq Global Market
PLL | Catalyst: Tax Inquiry -> Pall shares sink as company probes potential tax issues
PSSI | Catalyst: Earnings Guidance Lowered -> PSS World Medical Expects Lower Profit
SON | Catalyst: Poor Earnings -> Sonoco misses expectations, shares tumble
SPPI | Catalyst: Biotech/Drug Setback -> Biotech Stocks: Drug stocks mixed; Biovail tumbles on FDA rejection
WHR | Catalyst: Poor sales
X | Catalyst: Analyst Downgrade
No headlines
BIDU
GS
MLM
Posts
4 comments:
How do you determine if the float is low or not on the shares of a company?
BC
Below 25 million is preferable.
The price gap on KCI on Friday. Is that a sign that it could very well run quite a bit higher short term and long (especially given the gap was due to revised upward guidance on Friday)?
thanks
I don't think so. After looking at the numbers. Plus as a general observation gaps on such events on NYSE tend to retrace before continuing up. The market maker effect.
Post a Comment